Established In
Sales companies
Production Bases
R&D centers
Relybo leads in fluorine and sulfur building blocks with superior industrial chain advantages, offering products that stand out in the international market for their unbeatable quality and price.
As a Fluoro-containg compounds, 4-Bromo-3-fluoro-2-methylaniline (CAS 127408-03-1) is a critical building block in the synthesis of complex organic compounds. DUDLEY manufactures 4-Bromo-3-fluoro-2-methylaniline CAS: 127408-03-1 using refined synthetic processes and strict quality control measures to ensure a minimum purity of 99% min, meeting the rigorous standards of pharmaceutical and agrochemical industries. With comprehensive technical support and global supply capabilities, DUDLEY enables seamless integration of this intermediate into your production workflows, from lab-scale R&D to commercial-scale manufacturing.
3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole, with CAS number 131986-28-2, is a high-purity heterocyclic building block. It is globally recognized as the key strategic intermediate for the synthesis of Xanomeline (the active component of the blockbuster schizophrenia drug KarXT/Cobenfy). As a professional supplier, we provide commercial-scale supply with rigorous quality control to support the booming demand in the neurological drug market.
3,4-Difluoro-2-methoxyphenylacetic acid, with CAS number 1558274-26-2, is a high-purity fluorinated phenylacetic acid derivative. It is widely recognized as a critical strategic intermediate for the synthesis of next-generation non-opioid analgesics, specifically NaV1.8 inhibitors like Suzetrigine (VX-548). As a professional supplier, we ensure strict impurity control and consistent quality to support global pharmaceutical R&D and clinical trials.
Methyl 4-amino-2-pyridinecarboxylate, with CAS number 71469-93-7, is a high-purity pyridine derivative widely recognized as a critical intermediate in pharmaceutical synthesis (especially for anticancer drugs like Sorafenib). As a professional supplier, we adhere to strict quality control standards throughout the production process, ensuring our product meets the rigorous requirements of global pharmaceutical R&D and API manufacturing industries.
1,2-Ethanedithiol (CAS 540-63-6) is a high-purity organosulfur compound featuring two thiol (-SH) groups attached to an ethylene backbone, presented as a clear to pale green liquid. With a high purity of 99.9% (GC), this versatile chemical serves as a critical building block in organic synthesis, metal coordination chemistry, and pharmaceutical manufacturing. Engineered for consistency and reliability, our 1,2-Ethanedithiol meets the stringent quality requirements of research laboratories and industrial-scale production facilities worldwide, enabling precise and efficient synthetic processes across diverse applications.
Dudley holds qualifications:
Organic Sulphur building blocks(200+)
Organic Fluorine building blocks(100+)
News dated April 1, 2026: The U.S. FDA officially approved the launch of Eli Lilly’s Orforglipron under the brand name Foundayo. It is the II orally administered GLP-1 weight-loss drug approved worldwide, marking that the global weight management market is officially stepping into a new oral-dominated era from the injection-dominated era. With the steadily rising number of diabetic and obese patients across the globe, Orforglipron stands out as a revolutionary oral medication. Differing from traditional injectable medicines, it is an oral non-peptide small-molecule drug that greatly improves medication convenience for patients. Since Orforglipron entered the commercialization phase on April 1, 2026, the R&D and industrial production of its core intermediates have drawn wide attention in the industry. This approval is of milestone significance for the Chinese market. Up to now, Orforglipron is the only oral GLP-1 weight loss drug that has submitted marketing applications for obesity and overweight indications in China, and is highly likely to become the first approved oral GLP-1 weight loss drug in China. The landscape of the hundred-billion-level weight loss pharmaceutical track is poised to be completely reshaped by this oral drug. Orforglipron Target: GLP-1R Originator: Chugai Pharmaceutical Co., Ltd. Developers: Eli Lilly & Co., Eli Lilly Canada, Inc., Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd. Indications Under Development: Obesity, Overweight, Type 2 Diabetes Mellitus Highest R&D Phase: Approved for marketing First Approval Date: 2026-04-01 First Approved Country/Region: United States Orforglipron Starting Materials and Intermediates Intermediates Name CAS NO. 4-Bromo-3-fluoro-2-methylaniline 127408-03-1 5-Bromo-4-fluoro-1H-indazole 1082041-85-7 Ethyl 5-bromo-1H-indole-2-carboxylate 16732-70-0 5-bromo-2-indolecarboxylic acid 7254-19-5 (S)-3-Aminobutanenitrile hydrochloride 1073666-54-2 4-Bromo-2,6-dimethylfluorobenzene 99725-44-7 3-Fluoro-2-methylaniline 443-86-7 RELYBO is committed to providing global customers with high-purity, high-quality Orforglipron intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.
Xanomeline, an old drug Xanomeline is an old drug. Back in the 1990s, Novo Nordisk and Eli Lilly carried out a large number of clinical trials on it, mainly for the indication of Alzheimer's disease (AD). Regrettably, the trials were forced to terminate in 1998 owing to its notable gastrointestinal and cardiovascular side effects. Old drugs regain brand-new vitality! Cobenfy (Xanomeline/Trospium) emerges as a novel therapeutic agent for schizophrenia. In the early 2000s, Danish scientists accidentally discovered that xanomeline also exerts anti-schizophrenic activity. Karuna Therapeutics acquired its global development rights and redesigned its formula and dosage regimen. The company ingeniously combined xanomeline with trospium chloride to develop the combination drug KarXT, which effectively alleviated the gastrointestinal side effects caused by xanomeline. On September 26, 2024, the U.S. FDA officially approved Cobenfy (Xanomeline/Trospium) for oral treatment of schizophrenia in adult patients. It marks the first schizophrenia drug with an innovative mechanism of action to gain approval in 35 years. Impressively, Cobenfy generated revenue of 10 million US dollars within just two months after its launch, fully demonstrating its tremendous commercial potential. Xanomeline Target: M1 receptor × M4 receptor Originator: Eli Lilly & Co., Novo Nordisk A/S Developers: Bristol Myers Squibb Co., Karuna Therapeutics, Inc., Bristol Myers Squibb (China) Investment Co., Ltd. Indications Under Development: Agitation, Alzheimer’s Disease, Dementia-related Agitation Highest R&D Phase: Phase 3 Clinical Trial First Approval Date: Not yet approved First Approved Country/Region: Not yet approved Xanomeline Starting Materials and Intermediates Intermediates Name CAS NO. Pyridine-3-carbaldehyde 500-22-1 3-(4-Chloro-1,2,5-thiadiazol-3-yl)pyridine 131986-28-2 3-(4-HEXYLOXY-1,2,5-THIADIAZOL-3-YL)-1-METHYLPYRIDINIUM IODIDE 131988-19-7 RELYBO is committed to providing global customers with high-purity, high-quality Xanomeline intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.
On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets — a first-in-class non-opioid analgesic — for the treatment of moderate to severe acute pain in adults. Pain is a common medical condition, and relieving pain is a key therapeutic goal. Acute pain refers to short-term pain, typically caused by some form of tissue injury such as trauma or surgery. It is often treated with analgesics, which may or may not contain opioids. The U.S. FDA has long supported the development of non-opioid analgesics, primarily to address the severe opioid abuse crisis by reducing opioid prescriptions and overdose deaths, while filling the treatment gap for moderate-to-severe acute pain and providing patients with safer, low-addiction treatment options. Suzetrigine Target: Nav1.8 Originator: Vertex Pharmaceuticals, Inc. Developers: Vertex Pharmaceuticals, Inc. Indications Under Development: Acute Pain Highest R&D Phase: Approved for marketing First Approval Date: 2025-01-30 First Approved Country/Region: United States Suzetrigine Starting Materials and Intermediates Intermediates Name CAS NO. Methyl 2,3,4-trifluorobenzoate 773873-68-0 2,3,4-Trifluorobenzoic acid 61079-72-9 3-2-(3,4-Difluoro-2-methoxyphenyl)acetic acid 3-2-(3,4-Difluoro-2-methoxyphenyl)acetic acid Methyl 4-aminopyridine-2-carboxylate 71469-93-7 Methyl 4-chloropyridine-2-carboxylate 24484-93-3 RELYBO is committed to providing global customers with high-purity, high-quality Suzetrigine intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization of oral GLP-1 therapies.
On the evening of March 18, 2026, Johnson & Johnson announced that its oral peptide drug Icotrokinra (brand name: ICOTYDE) has been approved by the FDA for the treatment of moderate to severe plaque psoriasis (PsO) in adolescents aged 12 years and older and adults. It is the world’s first and only targeted oral peptide drug that blocks the IL-23 receptor. Icotrokinra Target: IL-23R Originator: Janssen Biotech, Inc. Developers: Janssen Research & Development LLC, Janssen (China) Investment Co., Ltd., Janssen Pharmaceutica NV Indications Under Development: Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis Highest R&D Phase: Approved for Marketing First Approval Date: 2026-03-17 First Approved Country/Region: United States Icotrokinra Starting Materials and Intermediates Intermediates Name CAS NO. 2-Naphthaldehyde 66-99-9 4-3-(Naphthalen-2-yl)-2-oxopropanoic acid 111726-64-8 trans-3-(3-Pyridyl)acrylic acid 19337-97-4 7-Methylindole 933-67-5 DL-Penicillamine 52-66-4 L-penicillamine 1113-41-3 RELYBO is committed to providing global customers with high-purity, high-quality Icotrokinra intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.
On June 18, 2025, Gilead Sciences officially announced via its official website that Yeztugo® (Lenacapavir) has become the first and only FDA-approved HIV prevention drug that provides six months of protective efficacy. Compared with daily oral medication, it features greater convenience and higher medication adherence, especially ideal for people who struggle to stick to daily oral regimens. Approved Indication(s)： First approved indication: On August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. Newly approved indication: On June 18, 2025 local time, the U.S. FDA approved lenacapavir for HIV pre-exposure prophylaxis in adolescents and adults weighing over 35 kg under the brand name Yeztugo. It is the world’s first PrEP regimen requiring only two injections per year. In China, On January 2, 2025, the National Medical Products Administration (NMPA) officially approved lenacapavir tablets and lenacapavir injection for marketing in China. On July 25, 2025, lenacapavir, an HIV pre-exposure prophylaxis (PrEP) drug requiring only two injections per year, was officially launched at the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. Lenacapavir Target: HIV-1 capsid Originator: Gilead Sciences, Inc. Developers: Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, Gilead Sciences Ltd. Indications Under Development: HIV infection Highest R&D Phase: Approved for Marketing First Approval Date: 2022-08-17 for HIV treatment, 2025-6-18 for HIV prevention First Approved Country/Region: European Union, USA Lenacapavir Starting Materials and Intermediates Intermediates Name CAS NO. 1,2-Ethanedithiol 540-63-6 3,5-Difluorobenzyl bromide 141776-91-2 3-bromo-6-chloro-2-fluoroBenzonitrile 943830-79-3 RELYBO is committed to providing global customers with high-purity, high-quality Lenacapavir intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.
On March 24, 2026, a major breakthrough was achieved in the treatment of chronic spontaneous urticaria (CSU). Remibrutinib, a novel oral targeted drug, was officially dispensed its first prescription in China. The first prescription was issued in Tianjin, China by Professor Zhang Litao to a 21-year-old young patient. Professor Zhao Zuotao stated that second-generation antihistamines are currently the first-line treatment. To put it vividly, conventional antihistamines are like mopping up leaked water downstream, which only act on histamine that has already been released and fail to address the root cause. In contrast, remibrutinib works by turning off the tap directly. It precisely inhibits the Bruton’s tyrosine kinase (BTK) signaling pathway, suppresses mast cell activation at the source, blocks the release of histamine and other pro-inflammatory mediators, and fundamentally prevents the onset of symptoms. "The advantages of this small-molecule drug lie in its rapid efficacy. Many patients achieve rash control on the very first day of treatment. More importantly, it enables long-term disease control and sustains symptom relief for up to one consecutive year, freeing patients from recurrent itching and helping them restore a normal quality of life," Professor Zhao emphasized. As the first approved oral small-molecule targeted agent for CSU, remibrutinib obtained rapid approval via the priority review pathway of the National Medical Products Administration (NMPA). The dispensing of its first prescription brings new hope to numerous patients stuck in treatment dilemmas. Sep 30, 2025， Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU). Remibrutinib Target: BTK Originator: Novartis Pharma AG Developers: Novartis Pharmaceuticals Corp., Novartis Pharmaceuticals Canada, Inc., Novartis (China) Biomedical Research Co., Ltd. Indications Under Development: Chronic Spontaneous Urticaria, Myasthenia Gravis, Secondary Progressive Multiple Sclerosis Highest R&D Phase: Approved for Marketing First Approval Date: 2025-09-30 First Approved Country/Region: United States Remibrutinib Starting Materials and Intermediates Intermediates Name CAS NO. 4-Cyclopropyl-2-fluorobenzoic acid 1247927-81-6 2-Bromo-4-fluoro-6-nitrotoluene 502496-33-5 RELYBO is committed to providing global customers with high-purity, high-quality Remibrutinib intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.
For product inquiries, please contact us online. stanleyhe@relybopharma.com
Copyright @ RELYBO PHARMACHEMICAL CO., LTD All Rights Reserved.
Network Supported
leave a message
Scan to wechat :
Scan to whatsapp :
